Biogen (BIIB) announced topline results from the Phase 2 CELIA study evaluating diranersen; CELIA did not meet its primary endpoint assessing dose response for change from baseline on the Clinical Dementia Rating-Sum of Boxes at Week 76

Biogen’s announcement regarding the Phase 2 CELIA study failing to meet its primary endpoint is significant, reflecting concerns about the trial's effectiveness.

Newsquawk StaffPublished 14 May 2026, 11:19 UTCOn the live feed at 10:59 UTC — 5 more headlines followed before this page went public

Newsquawk headlinesUTC

11:05

US Secretary of State Rubio says US policy on Taiwan is unchanged, according to NBC News; Trump and Xi found common ground on Iran

11:03

A Downing Street insider told the FT that PM Starmer was “going nowhere” and that Labour Party managers believe that Streeting’s support on Thursday had only reached the forties, FT reports

10:59

Biogen (BIIB) announced topline results from the Phase 2 CELIA study evaluating diranersen; CELIA did not meet its primary endpoint assessing dose response for change from baseline on the Clinical Dementia Rating-Sum of Boxes at Week 76

10:58

Tata Motors PV (TMPV IS) - Q4 (INR): Net income 57.8bln (exp. 43.5bln)

10:56

AT&T (T), T-Mobile (TMUS), Verizon (VZ) to launch new JV that helps wireless 'dead zones'

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free

Free. No signup, no card.

Based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational development.
VP says: "We are excited by these Phase 2 data, which give us the confidence to advance diranersen to registrational development".

Context

However, the company plans to move forward with diranersen based on encouraging biomarker and efficacy data, indicating that they see potential value despite the missed endpoint. This mixed result could impact investor sentiment, as it highlights both challenges and optimistic future prospects for the drug's development.

Equities · last 90 days

Recent headlines that moved markets

EQUITIES/8 Sept · 05:24 UTC

Saudi Energy Minister says a number of energy facilities and utilities were hit; are temporarily halting some operations.

Equity indices, after we published−0.3%

Modest downside seen across equity futures as energy prices tick higher.

EQUITIES/3 Sept · 04:54 UTC

North Korea stripped references to "peaceful unification" with South Korea from the charter of its ruling Workers' Party of Korea, according to Yonhap.

Equity indices, after we published−3.3%

EQUITIES/1 Sept · 16:17 UTC

Initial reports of an American attack on Iran, reports i24's Stein.

ES, after we published−0.2%

EQUITIES/26 Aug · 12:56 UTC

States and Meta (META) and agree to settle claims that platforms harmed children, according to a court filing; Meta agrees to pay a maximum of USD 16.68bln to states as part of deal

Market, after we published+2.6%

EQUITIES/7 Sept · 10:54 UTC

Saudi Aramco Jizan oil facilities were reportedly hit in new strikes, the FT reports citing sources; hit on Monday, damage is being assessed.

Equity indices, after we published−0.1%

EQUITIES/7 Sept · 09:15 UTC

Volkswagen (VOW3 GY) says that the Co., Lower Saxony and Aurelius Capital have agreed on key terms for the sale of Osnabrueck Plant; aims to secure the site and majority of jobs in the long term.

Market, after we published+1.6%

Newsquawk Daily

Get both market opens in your inbox.

This note and the other one — the EU open and the US open, every business day, written by the desk. No account needed.

Related headlines

The whole workspace, free to try.

© 2026 Newsquawk. All rights reserved.